Empowered Funds LLC Takes Position in Integra LifeSciences Holdings Co. (NASDAQ:IART)

Empowered Funds LLC purchased a new stake in shares of Integra LifeSciences Holdings Co. (NASDAQ:IART) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 7,923 shares of the life sciences company’s stock, valued at approximately $180,000.

A number of other institutional investors have also recently made changes to their positions in the stock. KBC Group NV raised its stake in Integra LifeSciences by 65.2% during the 3rd quarter. KBC Group NV now owns 2,839 shares of the life sciences company’s stock worth $52,000 after acquiring an additional 1,120 shares during the period. Nisa Investment Advisors LLC raised its position in shares of Integra LifeSciences by 599.6% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,267 shares of the life sciences company’s stock valued at $74,000 after buying an additional 2,800 shares during the last quarter. Centiva Capital LP bought a new stake in shares of Integra LifeSciences during the third quarter valued at approximately $192,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of Integra LifeSciences during the third quarter valued at approximately $198,000. Finally, Romano Brothers AND Company bought a new stake in shares of Integra LifeSciences during the fourth quarter valued at approximately $204,000. Hedge funds and other institutional investors own 84.78% of the company’s stock.

Integra LifeSciences Price Performance

IART stock opened at $21.13 on Friday. The firm has a market capitalization of $1.63 billion, a P/E ratio of -234.75, a P/E/G ratio of 0.73 and a beta of 1.17. Integra LifeSciences Holdings Co. has a 1 year low of $16.81 and a 1 year high of $45.11. The business’s 50-day moving average is $23.71 and its two-hundred day moving average is $21.81. The company has a debt-to-equity ratio of 0.79, a current ratio of 1.20 and a quick ratio of 0.73.

Wall Street Analysts Forecast Growth

IART has been the topic of several recent analyst reports. Citigroup lifted their price objective on shares of Integra LifeSciences from $16.00 to $22.00 and gave the company a “sell” rating in a research report on Tuesday, November 5th. Morgan Stanley initiated coverage on shares of Integra LifeSciences in a research report on Monday, December 2nd. They set an “underweight” rating and a $20.00 price objective on the stock. Three investment analysts have rated the stock with a sell rating, five have given a hold rating and one has issued a buy rating to the company. According to MarketBeat.com, Integra LifeSciences presently has a consensus rating of “Hold” and an average target price of $23.00.

Insider Activity

In other Integra LifeSciences news, EVP Michael J. Mcbreen sold 1,700 shares of the stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $24.16, for a total transaction of $41,072.00. Following the transaction, the executive vice president now owns 56,182 shares of the company’s stock, valued at $1,357,357.12. This trade represents a 2.94 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Company insiders own 3.10% of the company’s stock.

Integra LifeSciences Profile

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.